Skip to content

Study · Animal study (in vivo) · mouse · 2016

7 results

Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.

Hernández C, Bogdanov P, Corraliza L, García-Ramírez M, Solà-Adell C, Arranz JA, Arroba AI, Valverde AM, Simó R

Diabetes17 Sept 2015Cited by 230 (Europe PMC)

PMID26384381 (opens in a new tab)DOI10.2337/db15-0443 (opens in a new tab)PepBankPUB-26384381
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, systemic liraglutide prevented retinal neurodegeneration, including glial activation, neural apoptosis, and electroretinographical abnormalities.

    In plain wordsIn diabetic mice, systemic liraglutide prevented retinal nerve damage.

    Peptide
    Liraglutide
    Outcome
    DecreaseRetinal neurodegeneration after systemic administration
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    Moreover, we have demonstrated that systemic administration of a GLP-1R agonist (liraglutide) prevents retinal neurodegeneration (glial activation, neural apoptosis, and electroretinographical abnormalities).
  2. 02AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, systemic liraglutide significantly reduced extracellular glutamate as part of its retinal neuroprotective effect.

    In plain wordsIn diabetic mice, systemic liraglutide reduced extracellular glutamate in the retina.

    Peptide
    Liraglutide
    Outcome
    DecreaseExtracellular glutamate
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    This effect can be attributed to a significant reduction of extracellular glutamate and an increase of prosurvival signaling pathways.
    1 context sentence
    Summary · context
    Moreover, we have demonstrated that systemic administration of a GLP-1R agonist (liraglutide) prevents retinal neurodegeneration (glial activation, neural apoptosis, and electroretinographical abnormalities).
  3. 03AnimalAnimal study (in vivo)Mechanism

    In diabetic mice, systemic liraglutide increased prosurvival signaling pathways as part of its retinal neuroprotective effect.

    In plain wordsIn diabetic mice, systemic liraglutide increased retinal cell-survival signaling.

    Peptide
    Liraglutide
    Outcome
    IncreaseProsurvival signaling pathways
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · systemicAs given in this study (mouse).

    Source sentences

    Summary
    This effect can be attributed to a significant reduction of extracellular glutamate and an increase of prosurvival signaling pathways.
    1 context sentence
    Summary · context
    Moreover, we have demonstrated that systemic administration of a GLP-1R agonist (liraglutide) prevents retinal neurodegeneration (glial activation, neural apoptosis, and electroretinographical abnormalities).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, topical liraglutide showed retinal neuroprotection similar to systemic administration.

    In plain wordsIn diabetic mice, liraglutide eye drops protected retinal nerves similarly to systemic treatment.

    Peptide
    Liraglutide
    Outcome
    IncreaseRetinal neuroprotection after topical administration
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    We have found a similar neuroprotective effect using topical administration of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).
    1 context sentence
    Summary · context
    2) to determine the retinal neuroprotective effects of systemic and topical administration (eye drops) of GLP-1R agonists in db/db mice;
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, topical lixisenatide showed a similar retinal neuroprotective effect.

    In plain wordsIn diabetic mice, lixisenatide eye drops protected retinal nerves.

    Peptide
    Lixisenatide
    Outcome
    IncreaseRetinal neuroprotection after topical administration
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Neuroprotection · Eye
    Studied dose
    Dose not stated · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    We have found a similar neuroprotective effect using topical administration of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).
    1 context sentence
    Summary · context
    2) to determine the retinal neuroprotective effects of systemic and topical administration (eye drops) of GLP-1R agonists in db/db mice;
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, topical liraglutide-associated retinal neuroprotection occurred without reduced blood glucose.

    In plain wordsIn diabetic mice, liraglutide eye drops protected retinal nerves without reducing blood glucose.

    Peptide
    Liraglutide
    Outcome
    No significant changeBlood glucose during neuroprotection
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    Notably, this neuroprotective action was observed without any reduction in blood glucose levels.
    1 context sentence
    Summary · context
    We have found a similar neuroprotective effect using topical administration of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, topical lixisenatide-associated retinal neuroprotection occurred without reduced blood glucose.

    In plain wordsIn diabetic mice, lixisenatide eye drops protected retinal nerves without reducing blood glucose.

    Peptide
    Lixisenatide
    Outcome
    No significant changeBlood glucose during neuroprotection
    Study

    mousen: not reported in source

    Diabetic db/db mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · topical eye dropsAs given in this study (mouse).

    Source sentences

    Summary
    Notably, this neuroprotective action was observed without any reduction in blood glucose levels.
    1 context sentence
    Summary · context
    We have found a similar neuroprotective effect using topical administration of native GLP-1 and several GLP-1R agonists (liraglutide, lixisenatide, and exenatide).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.